270 related articles for article (PubMed ID: 23598481)
1. The need and challenges for development of an Epstein-Barr virus vaccine.
Cohen JI; Mocarski ES; Raab-Traub N; Corey L; Nabel GJ
Vaccine; 2013 Apr; 31 Suppl 2(0 2):B194-6. PubMed ID: 23598481
[TBL] [Abstract][Full Text] [Related]
2. Vaccine Development for Epstein-Barr Virus.
Cohen JI
Adv Exp Med Biol; 2018; 1045():477-493. PubMed ID: 29896681
[TBL] [Abstract][Full Text] [Related]
3. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults.
Sokal EM; Hoppenbrouwers K; Vandermeulen C; Moutschen M; Léonard P; Moreels A; Haumont M; Bollen A; Smets F; Denis M
J Infect Dis; 2007 Dec; 196(12):1749-53. PubMed ID: 18190254
[TBL] [Abstract][Full Text] [Related]
4. Rabbits immunized with Epstein-Barr virus gH/gL or gB recombinant proteins elicit higher serum virus neutralizing activity than gp350.
Cui X; Cao Z; Chen Q; Arjunaraja S; Snow AL; Snapper CM
Vaccine; 2016 Jul; 34(34):4050-5. PubMed ID: 27291087
[TBL] [Abstract][Full Text] [Related]
5. The promise of a prophylactic Epstein-Barr virus vaccine.
Balfour HH; Schmeling DO; Grimm-Geris JM
Pediatr Res; 2020 Jan; 87(2):345-352. PubMed ID: 31641280
[TBL] [Abstract][Full Text] [Related]
6. Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination.
Stewart JP; Micali N; Usherwood EJ; Bonina L; Nash AA
Vaccine; 1999 Jan; 17(2):152-7. PubMed ID: 9987149
[TBL] [Abstract][Full Text] [Related]
7. High Epstein-Barr Virus Load and Genomic Diversity Are Associated with Generation of gp350-Specific Neutralizing Antibodies following Acute Infectious Mononucleosis.
Weiss ER; Alter G; Ogembo JG; Henderson JL; Tabak B; Bakiş Y; Somasundaran M; Garber M; Selin L; Luzuriaga K
J Virol; 2017 Jan; 91(1):. PubMed ID: 27733645
[TBL] [Abstract][Full Text] [Related]
8. Epstein Barr Virus: Development of Vaccines and Immune Cell Therapy for EBV-Associated Diseases.
Cui X; Snapper CM
Front Immunol; 2021; 12():734471. PubMed ID: 34691042
[TBL] [Abstract][Full Text] [Related]
9. A novel vaccine candidate based on chimeric virus-like particle displaying multiple conserved epitope peptides induced neutralizing antibodies against EBV infection.
Zhang X; Zhao B; Ding M; Song S; Kang Y; Yu Y; Xu M; Xiang T; Gao L; Feng Q; Zhao Q; Zeng MS; Krummenacher C; Zeng YX
Theranostics; 2020; 10(13):5704-5718. PubMed ID: 32483413
[No Abstract] [Full Text] [Related]
10. Construction of Epstein-Bar virus cocktail peptide fused with Fcγ of IgG: as a potential delivery system for vaccine development.
Amel Jamehdar S; Tabaei S; Mashkani B; Karimi R; Motallebnezhad M; Esmaili A
Bioengineered; 2019 Dec; 10(1):689-696. PubMed ID: 31739735
[TBL] [Abstract][Full Text] [Related]
11. Epstein-Barr virus: an important vaccine target for cancer prevention.
Cohen JI; Fauci AS; Varmus H; Nabel GJ
Sci Transl Med; 2011 Nov; 3(107):107fs7. PubMed ID: 22049067
[TBL] [Abstract][Full Text] [Related]
12. Epstein-barr virus vaccines.
Cohen JI
Clin Transl Immunology; 2015 Jan; 4(1):e32. PubMed ID: 25671130
[TBL] [Abstract][Full Text] [Related]
13. Progress, prospects, and problems in Epstein-Barr virus vaccine development.
Balfour HH
Curr Opin Virol; 2014 Jun; 6():1-5. PubMed ID: 24632197
[TBL] [Abstract][Full Text] [Related]
14. Immunization with Components of the Viral Fusion Apparatus Elicits Antibodies That Neutralize Epstein-Barr Virus in B Cells and Epithelial Cells.
Bu W; Joyce MG; Nguyen H; Banh DV; Aguilar F; Tariq Z; Yap ML; Tsujimura Y; Gillespie RA; Tsybovsky Y; Andrews SF; Narpala SR; McDermott AB; Rossmann MG; Yasutomi Y; Nabel GJ; Kanekiyo M; Cohen JI
Immunity; 2019 May; 50(5):1305-1316.e6. PubMed ID: 30979688
[TBL] [Abstract][Full Text] [Related]
15. Designing an effective vaccine to prevent Epstein-Barr virus-associated diseases: challenges and opportunities.
Dasari V; Bhatt KH; Smith C; Khanna R
Expert Rev Vaccines; 2017 Apr; 16(4):377-390. PubMed ID: 28276306
[TBL] [Abstract][Full Text] [Related]
16. Soluble rhesus lymphocryptovirus gp350 protects against infection and reduces viral loads in animals that become infected with virus after challenge.
Sashihara J; Hoshino Y; Bowman JJ; Krogmann T; Burbelo PD; Coffield VM; Kamrud K; Cohen JI
PLoS Pathog; 2011 Oct; 7(10):e1002308. PubMed ID: 22028652
[TBL] [Abstract][Full Text] [Related]
17. Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.
Escalante GM; Mutsvunguma LZ; Muniraju M; Rodriguez E; Ogembo JG
Front Immunol; 2022; 13():867918. PubMed ID: 35493498
[TBL] [Abstract][Full Text] [Related]
18. A Pentavalent Epstein-Barr Virus-Like Particle Vaccine Elicits High Titers of Neutralizing Antibodies against Epstein-Barr Virus Infection in Immunized Rabbits.
Escalante GM; Foley J; Mutsvunguma LZ; Rodriguez E; Mulama DH; Muniraju M; Ye P; Barasa AK; Ogembo JG
Vaccines (Basel); 2020 Apr; 8(2):. PubMed ID: 32268575
[TBL] [Abstract][Full Text] [Related]
19. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation.
Khanna R; Moss DJ; Burrows SR
Immunol Rev; 1999 Aug; 170():49-64. PubMed ID: 10566141
[TBL] [Abstract][Full Text] [Related]
20. Protective immunization against Epstein-Barr virus-induced disease in cottontop tamarins using the virus envelope glycoprotein gp340 produced from a bovine papillomavirus expression vector.
Finerty S; Tarlton J; Mackett M; Conway M; Arrand JR; Watkins PE; Morgan AJ
J Gen Virol; 1992 Feb; 73 ( Pt 2)():449-53. PubMed ID: 1311367
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]